The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer
Launched by FUDAN UNIVERSITY · Mar 17, 2015
Trial Information
Current as of June 22, 2025
Completed
Keywords
ClinConnect Summary
This study is designed to compare the efficacy and safety of XELOX regimen with EOX regimen in the first-line treatment of advanced gastric cancer patients.
Gender
ALL
Eligibility criteria
- • Major inclusion criteria
- • had a histologically proven adenocarcinoma of the gastroesophageal junction, or stomach that was locally advanced (inoperable) or metastatic
- • measurable disease, according to the Response Evaluation Criteria in Solid Tumors (RECIST)1.1
- • an Eastern Cooperative Oncology Group performance status of 0 to 2
- • adequate renal, hepatic, and hematologic function
- • Major exclusion criteria
- • previous chemotherapy or radiotherapy (unless in the adjuvant setting)
- • uncontrolled cardiac disease, or other clinically significant, uncontrolled coexisting illness or previous or concurrent cancer
- • accumulated dose of Epirubicin exceeds 300mg/m2
- • HER2 positive and willing to use trastuzumab
About Fudan University
Fudan University, a prestigious comprehensive research university located in Shanghai, China, is committed to advancing medical science through innovative clinical research. Renowned for its rigorous academic standards and cutting-edge research facilities, Fudan University plays a pivotal role in the global health landscape by sponsoring a diverse array of clinical trials aimed at improving patient outcomes and addressing pressing medical challenges. Leveraging its multidisciplinary expertise and collaborative networks, the university strives to translate scientific discoveries into practical applications, fostering advancements in healthcare and contributing to the well-being of communities both locally and internationally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, Shanghai, China
Shanghai, Shanghai, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials